Suppressing the spread of tumors

Why some patients develop metastases and others do not is largely unclear. Researchers around ISTA professor Daria Siekhaus are now contributing to a better understanding of the process in certain types of cancer. They took a close look at the role of a protein called MFSD1 - the mammalian relative of a protein they had previously identified as affecting cell migration in fruit flies. Therefore, first author Marko Roblek from the Siekhaus group created mouse cancer cells lacking the protein. Without the protein, cells traveled much faster, suggesting that MFSD1 prevents the cells from moving. Together with collaborators from the University of Zurich, the team tested their theory in living mice with breast, colon, and skin cancer. "In the absence of MFSD1, there was a strong increase in metastasis," Daria Siekhaus summarizes the results.

Cancer cells resist starvation and stress

"We wanted to know why lower MFSD1 levels were beneficial to the tumor apart from allowing them to move more freely. As cancer cells travel through the blood for example, they experience a lot of mechanical stress," Marko Roblek explains. Thus, the researchers performed a stress test on cancer cells with and without the protein. Using a tiny rubber scraper, Roblek tried to scrape the cells off the surface of the Petri dish in which he had grown them. While the cancer cells containing MFSD1 quickly died under the mechanical stress, those without the protein tended to remain intact. Without the protein, the team concluded, certain tumor cells could more easily enter the bloodstream and find their way to other parts of the body. In another experiment, the researcher tested the cancer cell’s resistance to nutrient starvation with a similar result. Again, the cells lacking MFSD1 survived for longer.

Protein prevents detachment

The team was able to show that both the cell’s reaction to starvation and mechanical stress are caused by the protein MFSD1. It does so by affecting specific receptors located at the cell surface. These so called integrins ensure the cells stick to each other and the extracellular matrix, a dens network surrounding the cells in our body. In a constant circle, the cell produces these receptors, transports them to the cell surface and back inside the cell. If a tumor cell lacks MFSD1, they fail to recycle a certain type of integrin. "The result is, that the cells stick less to the surrounding tissue and each other, which makes it easier for them to migrate," says Daria Siekhaus.

Patient data supports findings

The team's findings are also supported by an analysis of patient data by Rita Seeböck from the University Hospital St. Pölten, Austria. The data, which is available online to researchers in anonymized form, showed a correlation between the level of MFSD1 and the patient's prognosis. "We've seen that patients suffering from specific forms of breast, gastric and lung cancer who had lower levels of MFSD1 had a worse outcome. A high level of MFSD1 seems to be protective - it works like a suppressor of tumor metastasis," cancer researcher Roblek says.

To optimize therapy for their patients, doctors are already analyzing the expression of certain genes. Now, they can also look for the gene encoding the protein MFSD1. "If this marker becomes more established, doctors can use it to help classify how aggressive the cancer is and to decide between different treatment options”, suggests biologist Daria Siekhaus. In future studies, the team wants to focus in detail on how the protein functions on a molecular level and is curious to learn if artificially raising the amount of MFSD1 could help suppress the spread of certain tumors. The long term goal is to examine if it can be used as a therapeutic target.

Roblek M, Bicher J, van Gogh M, György A, Seeböck R, Szulc B, Damme M, Olczak M, Borsig L, Siekhaus D.
The Solute Carrier MFSD1 Decreases the Activation Status of β1 Integrin and Thus Tumor Metastasis.
Frontiers in Oncology, 2022. doi: 10.3389/fonc.2022.777634

Most Popular Now

Positive Phase 1 data from mRNA-based individualiz…

BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability o...

FDA approves RIABNI™ (rituximab-arrx), a biosimila…

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with ...

Pfizer to invest $120 million to produce COVID-19 …

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Mic...

Proteomic study of 2,002 tumors identifies 11 pan-…

A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowled...

A new technology offers treatment for HIV infectio…

A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The s...

Broadly neutralizing antibodies could provide immu…

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published Ju...

Sanoff offers perspective on a promising rectal ca…

UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on ...

Boehringer Ingelheim signs option to acquire Truti…

Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. (the "Transaction"), a San Diego-based biotech company. Trutino Biosciences...

Novel drug combo activates natural killer cell imm…

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, the...

Novartis announces Nature Medicine publication of …

Novartis announced that Nature Medicine published final results from both the two- and three-copy cohorts of the completed Phase 3 SPR1NT trial as separate companion manu...

COVID-19 rebound after taking Paxlovid likely due …

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was ...

Biomarkers found that could be drug targets agains…

Biomarkers that could be targets for novel drugs to treat glioblastoma brain tumors have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Cent...